Jump to navigation Jump to search
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass386.567 g/mol

WikiDoc Resources for HU-210


Most recent articles on HU-210

Most cited articles on HU-210

Review articles on HU-210

Articles on HU-210 in N Eng J Med, Lancet, BMJ


Powerpoint slides on HU-210

Images of HU-210

Photos of HU-210

Podcasts & MP3s on HU-210

Videos on HU-210

Evidence Based Medicine

Cochrane Collaboration on HU-210

Bandolier on HU-210

TRIP on HU-210

Clinical Trials

Ongoing Trials on HU-210 at Clinical

Trial results on HU-210

Clinical Trials on HU-210 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on HU-210

NICE Guidance on HU-210


FDA on HU-210

CDC on HU-210


Books on HU-210


HU-210 in the news

Be alerted to news on HU-210

News trends on HU-210


Blogs on HU-210


Definitions of HU-210

Patient Resources / Community

Patient resources on HU-210

Discussion groups on HU-210

Patient Handouts on HU-210

Directions to Hospitals Treating HU-210

Risk calculators and risk factors for HU-210

Healthcare Provider Resources

Symptoms of HU-210

Causes & Risk Factors for HU-210

Diagnostic studies for HU-210

Treatment of HU-210

Continuing Medical Education (CME)

CME Programs on HU-210


HU-210 en Espanol

HU-210 en Francais


HU-210 in the Marketplace

Patents on HU-210

Experimental / Informatics

List of terms related to HU-210


HU-210 is a synthetic cannabinoid that was discovered around 1988 in the group of Dr Raphael Mechoulam at the Hebrew University. HU-210 is 100 to 800 times more potent than natural THC from cannabis and has an extended duration of action.[1] HU-210 is the (+)-1,1-dimethylheptyl analog of 7-hydroxy-delta-6-tetrahydrocannabinol. The abbreviation HU stands for Hebrew University.

Per a 2005 article in the Journal Of Clinical Investigation, HU-210 with daily high doses over a few weeks stimulates neural growth in rats' hippocampus region, the opposite effect of drugs like alcohol, nicotine, heroin, and cocaine. It was also indicated by this increased neural growth to entail antianxiety and antidepressant effects.

HU-210, along side WIN 55,212-2 and JWH-133, is implicated in preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers. This anti-inflammatory action is induced through the agonization of cannabinoid receptors which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.

HU-210 is a potent analgesic with many of the same effects as natural THC. This means that HU-210 could potentially be used in medicine as an alternative to medical marijuana, however its much stronger and longer lasting effects compared to those of THC could make appropriate titration of dosage difficult. Also because HU-210 is a CB1 full agonist as opposed to THC which is a partial agonist, the sedative effects of HU-210 are much more prominent, meaning that while fatal overdoses of THC itself are virtually impossible[2], they would be possible with HU-210.

External links

  • Wen Jiang; et al. (2005). "Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic and antidepressant-like effects". The Journal of Clinical Investigation. Scientific article about nerve cell growth.
" ignored (help) Comment in Nature on the article.  

de:Dexanabinol it:HU-210

Template:WH Template:WikiDoc Sources